The Lancet Haematology

Published by: Elsevier Science, Inc.  

People

  1. Giralt
    Giralt
  2. Hassoun
    Hassoun
  3. Landau
    Landau
  4. Landgren
    Landgren
  5. Matasar
    Matasar
  6. Noy
    Noy
  7. Papanicolaou
    Papanicolaou
  8. Scaradavou
    Scaradavou
  9. Younes
    Younes

Groups

  1. Center for Hematologic Malignancies (5)
  2. Hematologic Oncology, Division of (5)
  3. Lymphoma Service (3)
  4. Lymphoma (3)
  5. Lymphoma Disease Management Team (2)
  6. Myeloma Service (2)
  7. Population Sciences Research Program (2)
  8. Survivorship Research (2)
  9. Adult Bone Marrow Transplant (BMT) Service (1)
  10. Bone Marrow Transplant (1)
Search Within
Refine Results
Formats
  1. Journal Article (8)
Groups
  1. Center for Hematologic Malignancies (5)
  2. Hematologic Oncology, Division of (5)
  3. Lymphoma (3)
  4. Lymphoma Service (3)
  5. Lymphoma Disease Management Team (2)
  6. Myeloma Service (2)

More Groups

People
  1. Anas Younes (1)
  2. Andromachi Scaradavou (1)
  3. Ariela Noy (1)
  4. Carl Landgren (1)
  5. Genovefa Papanicolaou (1)
  6. Hani Hassoun (1)

More People

Years
  1. 2019 (1)
  2. 2018 (3)
  3. 2017 (3)
  4. 2016 (1)
Publishers
  1. Elsevier Science, Inc. (8)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1/2a study
    Journal Article

    Younes, A.; Brody, J.; Carpio, C.; Lopez-Guillermo, A.; Ben-Yehuda, D.; Ferhanoglu, B.; Nagler, A.; Ozcan, M.; Avivi, I.; Bosch, F.; more...
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: A prospective, multicentre, single-arm phase 2 study
    Journal Article

    Dunleavy, K.; Fanale, M. A.; Abramson, J. S.; Noy, A.; Caimi, P. F.; Pittaluga, S.; Parekh, S.; Lacasce, A.; Hayslip, J. W.; Jagadeesh, D.; more...
    The Lancet Haematology (2018)

    Fulltext@MSK | Save
  • Beyond maximum grade: Modernising the assessment and reporting of adverse events in haematological malignancies
    Journal Article

    Thanarajasingam, G.; Minasian, L. M.; Baron, F.; Cavalli, F.; De Claro, R. A.; Dueck, A. C.; El-Galaly, T. C.; Everest, N.; Geissler, J.; Gisselbrecht, C.; more...
    The Lancet Haematology (2018)

    Fulltext@MSK | Save
  • Predictive value of faecal adenoviral load for viraemia
    Journal Article

    Papanicolaou, G.
    The Lancet Haematology (2018)

    Fulltext@MSK | Save
  • Serum protein markers of clonal heterogeneity in myeloma
    Journal Article

    Landgren, O.
    The Lancet Haematology (2017)

    Fulltext@MSK | Save
  • Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: A randomised, double-blind, phase 3 trial
    Journal Article

    Holstein, S. A.; Jung, S. H.; Richardson, P. G.; Hofmeister, C. C.; Hurd, D. D.; Hassoun, H.; Giralt, S.; Stadtmauer, E. A.; Weisdorf, D. J.; Vij, R.; more...
    The Lancet Haematology (2017)

    Fulltext@MSK | Save
  • Unrelated cord blood transplantation for non-malignant diseases: Every HLA allele counts
    Journal Article

    Scaradavou, A.
    The Lancet Haematology (2017)

    Fulltext@MSK | Save
  • Lenalidomide in adult T-cell leukaemia-lymphoma
    Journal Article

    Moskowitz, A. J.
    The Lancet Haematology (2016)

    Fulltext@MSK | Save

    • The Lancet Haematology – authorized name for:

    Name ISSN / ISBN Publisher
    Lancet Haematology 2352-3026 Elsevier Science, Inc.
    Lancet Haematology 2352-3026 Elsevier Science, Inc.
    The Lancet Haematology 23523026 Unknown
    The Lancet Haematology 23523026 Elsevier Inc.
    The Lancet Haematology 2352-3026 Elsevier Science, Inc.
    The Lancet Haematology 2352-3026 Elsevier Inc.